Archive · 4 Oct 2025
Three Pharma Mutual Funds to Watch in 2026
The US is planning a big tax on medicines, which could affect the Indian pharma industry.
This has caused some uncertainty in the market.
However, history shows that the pharma industry often recovers.
This article highlights three mutual funds that have done well and could be worth considering for investment in 2026.
These funds include ICICI Prudential Pharma Healthcare & Diagnostics, DSP Healthcare Fund and SBI Healthcare Opp Fund.
These funds have shown good returns compared to others.
It is essential to remember that past success doesn't guarantee future results, and you should speak to a financial advisor before making any investment decisions.
US President announced a 100% tariff on branded drugs.
Pharma stocks faced a market correction because of the tariff announcement.
ICICI Prudential Pharma Healthcare & Diagnostics, DSP Healthcare Fund, and SBI Healthcare Opp Fund are highlighted.
These three funds have outperformed the benchmark.
Past performance is not an indicator of future returns, and investors should seek financial advice.
- Who
- Investors, ICICI, DSP, SBI Funds
- What
- Information on three pharma mutual funds to watch in 2026
- When
- Article published around September 28, 2025
- Where
- United States, India
- Why
- To provide investment insight regarding pharma funds.
Investors
Economic Analysts
Impact of US Tariffs
Investors
Acknowledging near-term turbulence from US tariffs, pharma is still seen as a resilient long-term theme.
Economic Analysts
Acknowledging near-term turbulence from US tariffs, pharma is still seen as a resilient long-term theme.
- Key Figure
- Donald Trump (US President)
- US Trade Action
- 100% Tariff on Branded Drugs
- Fund #1
- ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund
- Fund #2
- DSP Healthcare Fund
- Fund #3
- SBI Healthcare Opp Fund (G)
- Data as of
- September 28, 2025
